XML 63 R52.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Reportable Segments (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2016 | Sep. 30, 2015 | Sep. 30, 2016 | Sep. 30, 2015
Segment Reporting Information [Line Items] |  |  |  |  |  |  |
Sales |  | $ 203,930 |  | $ 264,047 | $ 644,782 |  | $ 779,404
Operating Income (Loss) |  | 20,064 |  | 15,609 | 55,040 |  | 55,695
Energy & Chemicals [Member] |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |
Sales |  | 23,711 |  | 78,388 | 122,865 |  | 257,197
Operating Income (Loss) | [1] | (5,736) |  | 10,795 | 14,190 |  | 45,626
Distribution & Storage [Member] |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |
Sales |  | 126,646 |  | 129,590 | 363,743 |  | 356,474
Operating Income (Loss) | [1] | 14,715 |  | 8,027 | 37,550 |  | 29,184
BioMedical [Member] |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |
Sales |  | 53,573 |  | 56,069 | 158,174 |  | 165,733
Operating Income (Loss) | [1] | 20,916 | [2] | 5,966 | 38,120 | [2] | 15,202
Corporate [Member] |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |
Operating Income (Loss) | [1] | (9,831) | [2] | $ (9,179) | (34,820) | [2] | $ (34,317)
Cost of Sales [Member] |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |
Gain (Loss) Related to Litigation Settlement |  | 15,145 |  |  | 15,145 |  |
Selling, General and Administrative Expenses [Member] |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |
Gain (Loss) Related to Litigation Settlement |  | $ 859 |  |  | $ 376 |  |
[1] | As described in Note 1, beginning in 2016, the Company allocates share-based compensation expense to each operating segment and maintains share-based compensation expense related to Corporate employees at Corporate. Prior to 2016, all share-based compensation expense was recorded at Corporate. Reclassifications from Corporate to the operating segments have been made to the 2015 results to conform to the 2016 presentation.
[2] | During the third quarter of 2016, the Company recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep Corporation under the related representation and warranty insurance. For the three months ended September 30, 2016, this reduced our BioMedical segment’s cost of sales by $15,145 and Corporate SG&A expenses by $859, net of associated legal fees. For the nine months ended September 30, 2016, this reduced our BioMedical segment’s cost of sales by $15,145 and Corporate SG&A expenses by $376, net of associated legal fees recorded in the first nine months of the year.

X
- Definition Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 + Details
Name: | us-gaap_GainLossRelatedToLitigationSettlement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=gtls_EnergyChemicalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=gtls_DistributionStorageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=gtls_BiomedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |